Defining Human Immunodeficiency Virus (HIV) Type 1 Immunotypes with Six Human Monoclonal Antibodies

AIDS Research and Human Retroviruses

Volumn 20, Issue 1, 2004, Pages 55-65

  Nádas, Arthur ^a   Zhong, Ping ^a,b   Burda, Sherri ^a   Zekeng, Leopold ^c   Urbanski, Mateusz ^a   Gorny, Miroslaw K ^a   Zolla Pazner, Susan ^a,d   Nyambi, Phillipe N ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Shanghai Munic Ctr Dis Contr P   (China)

^c Laboratoire de Sante Hygiene Mobile   (Cameroon)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ARTICLE; BINDING ASSAY; CLADISTICS; GENE CLUSTER; GENE IDENTIFICATION; GENETIC SIMILARITY; GENETIC VARIABILITY; IMMUNOGENICITY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRION; VIRUS CLASSIFICATION; VIRUS GENE; VIRUS ISOLATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; CAMEROON; CLUSTER ANALYSIS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS;

EID: 17644446121     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204322749503     Document Type: Article

References (40)

1. Nyambi PN, Nkengasong J, Lewi P, et al.: Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:6235-6243.
2. Gorny MK, VanCott TC, Hioe C, et al.: Human monoclonal antibodies to the V3 loop of HIV-1 with intra and inter-clade cross-reactivity. J Immunol 1997;159:5114-5122.
3. Conley AJ, Gorny MK, Kessler JA II, et al.: Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody, 447-52D. J Virol 1994;68:6994-7000.
4. Nyambi PN, Willems B, Janssens W, et al.: The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them. AIDS Res Hum Retroviruses 1997;13:7-17.
5. Beirnaert E, Nyambi P, Willems B, et al.: Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000;61:14-24.
6. Zolla-Pazner S, Gorny MK, Nyambi IN, VanCott TC, and Nádas A: Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV. J Virol 1999;73:4042-4051.
7. Nyambi IN, Nádas A, Mbah HA, et al.: Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 2000;74:10670-10680.
8. Nyambi PN, Mbah HA, Burda S, et al.: Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000;74:7096-7107.
9. Nyambi P, Zekeng L, Kenfack H, et al.: HIV infection in rural villages of Cameroon. J Acquir Immune Defic Syndr 2002;31: 506-513.
10. Zhong P, Burda S, Urbanski M, et al.: HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon. J Acquir Immune Defic Syndr 2002;31:495-505.
11. Korber B, Muldoon M, Theiler J, et al.: Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-1796.
12. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, and Hahn BH: The origins of acquired immune deficiency syndrome viruses: Where and when? Philos Trans R Soc Lond B Biol Sci 2001;356:867-876.
13. Yusim K, Peeters M, Pybus OG, et al.: Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. Philos Trans R Soc Lond B Biol Sci 2001;356:855-866.
14. Nyambi P, Heyndrickx L, Vereecken K, et al.: Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns. AIDS 2002 16:295-296.
15. Nyambi PN, Nkengasong J, Peeters M, et al.: Reduced capacity of antibodies from patients infected with human immunodeficiency virus type-1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis 1995;172: 1228-1237.
16. Nyambi PN, Burda S, Bastiani L, and Williams C: A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1. J Immunol Methods 2001;253:253-262.
17. Delwart EL, Shpaer EG, Louwagie J, et al.: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
18. Gorny MK, Gianakakos V, Sharpe S, and Zolla-Pazner S: Generation of human monoclonal antibodies to HIV. Proc Natl Acad Sci USA 1989;86:1624-1628.
19. Gigler A, Dorsch S, Hemauer A, et al.: Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999;73:1974-1979.
20. Gorny MK, Xu J-Y, Gianakakos V, et al.: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 1991;88:3238-3242.
21. Gorny MK, Xu J-Y, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp 120. J Immunol 1993;150: 635-643.
22. Gorny MK and Zolla-Pazner S: Recognition of free and complexed peptides representing the prefusogenic and fusogenic forms of HIV-1 gp41 by human monoclonal antibodies. J Virol 2000;74: 6186-6192.
23. Nyambi PN, Gorny MK, Bastiani L, van der Groen G, Williams C, and Zolla-Pazner S: Mapping of epitopes exposed on intact HIV-1 virions: A new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998;72:9384-9391.
24. Nyambi PN, Lewi P, Peeters M, et al.: Study of the dynamics of neutralizing escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus (SIVcpz-ant). J Virol 1997;71: 2320-2330.
25. Andries K, Dewindt B, Snoeks J, et al.: Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogencity. J Virol 1990;64: 1117-1123.
26. Lewi PJ: Spectral mapping, a technique for classifying biological activity profiles of chemical compounds. Arzneimittelforschung 1976;26:1295-1300.
27. Nádas A: Binary classification by stochastic neural nets. Trans Neural Networks 1995;6:488-491.
28. Nádas A: Hidden Markov models and some connections with artificial neural nets. In: Mathematical Perspectives on Neural Networks (Smolensky P, et al., ed.). Lawrence Erlbaum Associates, Mahwah, NJ, 1995.
29. Bryk AS and Raudenbush SW: Hierarchial Linear Models: Applications and Data Analysis Methods. Sage Publications, Newbury Park, CA, 1992.
30. Carlin BP and Louis TA: Bayes and Empirical Bayes Methods for Data Analysis, Chapman and Hall, London, 1996.
31. Gorny MK, Conley AJ, Karwowska S, et al.: Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
32. Gorny MK, VanCott TC, Williams C, Revesz K, and Zolla-Pazner S: Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology 2000; 267:220-228.
33. Hochleitner EO, Gorny MK, Zolla-Pazner S, and Tomer KB: Mass spectrometric characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A. J Immunol 2000;164:4156-4161.
34. Gorny MK, Williams C, Volsky B, et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J Virol 2002;76:9035-9045.
35. Moore JP, Trkola A, Korber B, et al.: A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995;69:122-130.
36. Trkola A, Pomales AB, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tertrameric CD4-IgG. J Virol 1995;69:6609-6617.
37. Kostrikis LG, Cao Y, Ngai H, Moore JP, and Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996;70:445-458.
38. Weber J, Fenyo E-M, Beddows S, Kaleebu P, and Bjorndal A, The WHO Committee for HIV Isolation Characterization: Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtype. J Virol 1996;70:7827-7832.
39. Zolla-Pazner S, O'Leary J, Burda S, et al.: Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995;69:3807-3815.
40. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp 120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.